Yoshihiro Arai

Chief Executive Officer at SOLASIA PHARMA K.K.

Net worth: 190 754 $ as of 30/04/2024

63 year

Health Technology

Consumer Services

Yoshihiro Arai active positions

Companies	Position	Start	End
SOLASIA PHARMA K.K.	Director/Board Member	01/02/2013	-
	Chief Executive Officer	01/02/2013	-
	President	01/02/2013	-
	Corporate Officer/Principal	01/09/2007	01/02/2013

Companies	Position	Start	End
Searle Yakuhin KK	Corporate Officer/Principal	-	-
Amgen KK Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million.	Corporate Officer/Principal	-	-

University of Wales (Bangor)	Masters Business Admin
Tokyo University of Pharmacy & Life Science	Graduate Degree

International

Japan	5
United Kingdom	2

Operational

Corporate Officer/Principal	3
Director/Board Member	1
Chief Executive Officer	1

Sectoral

Health Technology	3
Consumer Services	3

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	1
SOLASIA PHARMA K.K.	Health Technology

Private companies	2
Amgen KK Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million.	Health Technology
Searle Yakuhin KK

Private companies

Health Technology

Searle Yakuhin KK